VBIV VBI Vaccines
- 0.574
- -0.025-4.24%
- 0.588
- +0.014+2.44%
VBI Vaccines News
Express News | Perceptive Advisors LLC - Had Previously Reported 5.8% Stake in VBI Vaccines as of Nov 17, 2023
Express News | Perceptive Advisors LLC Reports 4.4% Stake in VBI Vaccines as of April 16 - SEC Filing
Express News | VBI Vaccines Inc : Raymond James Cuts Target Price to $5 From $6
VBI Vaccines FY Non-GAAP EPS of $3.96
VBI Vaccines Soars With Hepatitis B Vaccine Success
VBI Vaccines 2023 Rev $8.7M >VBIV
VBI Vaccines 2023 Rev $8.7M >VBIV
Express News | VBI Vaccines Reports Full Year 2023 Financial Results
VBI Vaccines Raises $1.7 Million in Direct Share Offering
Express News | VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
Express News | VBI Vaccines Shares Are Trading Lower After the Company Announced a $2 Million Registered Direct Offering at $0.88 per Share
Express News | VBI Vaccines Announces $2M Registered Direct Offering At $0.88/Share
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into definitive agreements for
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ:BPTS) rose sharply in today's pre-market trading after reporting FY23 results. Biophytis posted a FY23 loss of €0.03 per share, versus a year-ago loss of €0.14 per s
VBI Vaccines Inc Release: Content Unintelligible
VBI Vaccines to Present Early Phase 2b Cancer Vaccine Results
Express News | VBI Vaccines Presents Early Tumor Response Data From Randomized Controlled Phase 2b Study Of VBI-1901 In Recurrent Glioblastoma; Early Data From Patients Eligible For Evaluation At Week 12 Show Two Observations Of Stable Disease, Indicating No Tumor Progr
VBI Vaccines Bolsters Collaboration With Canadian Government
Express News | VBI Vaccines Expands Collaboration With Canadian Government; Says Under The New Agreement, The Remaining C$28M Of Funding Available Under The Previously Committed C$56M Will Be Directed Toward The Development Of VBI's MLE Platform
Express News | VBI Vaccines To Expand Strategic Partnership With Canadian Government; Partnership To Direct CAD$28M Of Funding Remaining Under Original CAD$56M Award To Continue Development Of Proprietary Tech Platforms
Analysis
Price Target
No Data
